The Quell wearable pain relief device [Image courtesy of NeuroMetrix]ElectroCore (Nasdaq:ECOR) announced that it agreed to acquire NeuroMetrix  (Nasdaq:NURO) and its Quell neuromodulation platform.

Quell可穿戴止痛设备[图片由NeuroMetrix提供]ElectroCore（纳斯达克股票代码：ECOR）宣布同意收购NeuroMetrix（纳斯达克股票代码：NURO）及其Quell神经调节平台。

NeuroMetrix develops the Quell platform, a wearable, app- and cloud-enabled neuromodulation platform. It treats fibromyalgia symptoms and lower-extremity chronic pain. The company also offers DPNCheck, a point-of-care screening test for peripheral neuropathy. However, ElectroCore said it expects NeuroMetrix to divest that technology prior to the acquisition’s completion..

NeuroMetrix开发了Quell平台，这是一个可穿戴的，应用程序和云支持的神经调节平台。。该公司还提供DPNCheck，一种针对周围神经病变的即时筛查测试。然而，ElectroCore表示，预计NeuroMetrix将在收购完成之前剥离该技术。

Under the agreement, NeuroMetrix becomes a wholly owned subsidiary of ElectroCore. Chair and CEO Shai N. Gozani said the announcement “represents the culmination” of a strategic review process announced in February. Gozani said it “marks a positive outcome for the company’s shareholders” as well.

根据该协议，NeuroMetrix成为ElectroCore的全资子公司。主席兼首席执行官沙伊·戈扎尼（ShaiN.Gozani）表示，这一宣布“代表了2月份宣布的战略审查过程的高潮”。戈扎尼表示，这也“标志着公司股东取得了积极成果”

ElectroCore says the acquisition can accelerate its efforts to become “a significant player” in the bioelectronic health and wellness sector. The deal expands its product portfolio of non-invasive therapies for medical conditions and general wellness product offerings. It also expands its technological capabilities through the Quell mobile application and health cloud platform..

ElectroCore表示，此次收购可以加速其努力，成为生物电子健康和保健领域的“重要参与者”。该交易扩大了其针对医疗条件和一般健康产品的非侵入性治疗产品组合。它还通过Quell移动应用程序和健康云平台扩展了其技术能力。

NeuroMetrix said both companies’ boards approved the deal. They expect it to close late in the first quarter of 2025.

NeuroMetrix表示，两家公司的董事会都批准了这项交易。他们预计它将在2025年第一季度末关闭。

“We are confident we can leverage our established distribution channels, especially the VA Hospital System, to accelerate adoption of the Quell fibromyalgia solution,” stated Dan Goldberger, ElectroCore CEO. “NeuroMetrix has spent many years developing the Quell commercial asset, and ElectroCore has developed a strong commercial organization for our own prescription and direct-to-consumer nerve stimulation solutions.

ElectroCore首席执行官丹·戈德伯格（DanGoldberger）表示：“我们有信心利用我们已建立的分销渠道，特别是弗吉尼亚州医院系统，加速采用平息纤维肌痛的解决方案。”。“NeuroMetrix花了多年时间开发Quell商业资产，ElectroCore为我们自己的处方和直接面向消费者的神经刺激解决方案开发了强大的商业组织。

This acquisition will immediately increase our addressable market, and diversify our portfolio of non-pharmaceutical, non-invasive nerve stimulation offerings..

此次收购将立即扩大我们的目标市场，并使我们的非药物、非侵入性神经刺激产品组合多样化。

“Following the transaction, we expect ECOR to be the leading publicly traded neuromodulation platform focused on wellness and chronic pain.”

“交易完成后，我们预计ECOR将成为专注于健康和慢性疼痛的领先上市神经调节平台。”